adjuvanted quadrivalent influenza virus subunit vaccine

The adjuvanted quadrivalent influenza virus subunit vaccine is a seasonal vaccine candidate designed to protect against four strains of the influenza virus: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). As a subunit vaccine, it contains purified viral surface proteins, specifically hemagglutinin (HA) and neuraminidase (NA), rather than whole or split virions, which typically results in a better safety profile. The inclusion of an adjuvant is a critical feature intended to enhance the magnitude and breadth of the immune response, particularly in older adults (aged 65 and older) who often exhibit a diminished response to standard vaccines due to immunosenescence. This specific vaccine is being evaluated in clinical trials sponsored by the Hubei Provincial Center for Disease Prevention and Control to determine its safety, tolerability, and immunogenicity in the elderly population.

Other names

adjuvanted quadrivalent influenza subunit vaccineadjuvanted QIV subunit vaccine